Our earlier findings that epithelial ovarian cancer (EOC) is recognized by the host's immune response, and that activation of antitumor immune response is associated with longer survival, revive hopes that immune interventions might offer important therapeutic opportunities in EOC. However, current immune therapy approaches have generally insufficient power to induce rapid and oven/vhelming tumor rejection response. Over the past SPORE funding cycle, Drs Coukos, June and colleagues have launched a clinical immunotherapy program in ovarian cancer, made important advances in understanding mechanisms that disable or attenuate tumor immune attack, and developed tools to counteract these. We have found that tumor-infiltrating lymphocytes recognize autologous tumor and once expanded appropriately ex vivo, they can suppress tumor growth in vivo following adoptive transfer. We propose to test the central hvpothesis that it is now possible for the first time to deliver powerful immunotherapy for ovarian cancer capitalizing on tumor-infiltrating lymphocytes (TIL) optimized for adoptive therapy through advanced culture platforms we developed. A related hypothesis is that it is now possible to break the tumor barriers to immune attack by (a) restoring tumor antigen presentation and tumor recognition by T cells (Signal 1) through rational use of chemotherapy;and (b) restoring costimulatory activation of T cells at the tumor site (Signal 2) through engineering T cells with costimulatory chimeric immunoreceptors (CIRs) redirected against tumor antigens.
Specific Aim 1 will translate laboratory findings into adoptive lymphocyte therapy trials. A phase l/ll clinical trial will be conducted to test the hypothesis that appropriate costimulation ex vivo of TIL and host lymphodepletion augment the response to adoptive T cell transfer therapy.
Specific Aim 2 proposes to maximize T cell recognition of tumor (Signal 1) through use of chemotherapy. We will test the preclinical effect of combining adoptive TIL therapy with pegylated liposomal doxorubicin (Doxil) and define optimal schedules in order to move to the clinic a combination trial.
Specific Aim 3 proposes to maximize in vivo costimulation (Signal 2) through the use of chimeric immunoreceptors. We will test the preclinical efficacy of tumor-derived T cells engineered ex vivo to express costimulatory chimeric immunoreceptors recognizing a common EOC antigen, mesothelin.

Public Health Relevance

Current immune therapy approaches have generally insufficient power to induce rapid and ovenwhelming tumor rejection response. We assert that the advanced techniques for T cell production and pharmacologic and engineering interventions proposed are poised to resolve many of the current limitations in immunotherapy. If we are successful, our work will produce significant therapeutic increments in ovarian cancer and provide important technology for other tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
7P50CA083638-15
Application #
8474625
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
15
Fiscal Year
2013
Total Cost
$526,095
Indirect Cost
$126,401
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Xiao, Xue; Yang, Gong; Bai, Peng et al. (2016) Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway. BMC Cancer 16:582
Prudnikova, T Y; Villamar-Cruz, O; Rawat, S J et al. (2016) Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene 35:2178-85
Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50
Wang, Yifan; Bernhardy, Andrea J; Cruz, Cristina et al. (2016) The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res 76:2778-90
Zhang, Youyou; Feng, Yi; Hu, Zhongyi et al. (2016) Characterization of Long Noncoding RNA-Associated Proteins by RNA-Immunoprecipitation. Methods Mol Biol 1402:19-26
Hu, Xiaowen; Feng, Yi; Hu, Zhongyi et al. (2016) Detection of Long Noncoding RNA Expression by Nonradioactive Northern Blots. Methods Mol Biol 1402:177-88
Zhang, Youyou; He, Qun; Hu, Zhongyi et al. (2016) Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nat Struct Mol Biol 23:522-30
Beck, Tim N; Korobeynikov, Vladislav A; Kudinov, Alexander E et al. (2016) Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Rep 16:657-71
Zhang, Shiwu; Mercado-Uribe, Imelda; Sood, Anil et al. (2016) Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes Cancer 7:60-72
Daly, Mary B; Dresher, Charles W; Yates, Melinda S et al. (2015) Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res (Phila) 8:342-8

Showing the most recent 10 out of 303 publications